Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535360 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT06535360 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 150 participants.
The verdict
NCT06535360, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a prospective randomized clinical trial designed to determine the hemostatic ability of pathogen reduced platelet, when compared to non-pathogen reduced platelets suspended in platelet additive solution.
Interventions
- BIOLOGICAL Platelet transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06535360
The ClinicalTrials.gov registry entry for NCT06535360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Platelet transfusion is the first listed.
NCT06535360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06535360 about?
NCT06535360 is a clinical study titled "Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion". This is a prospective randomized clinical trial designed to determine the hemostatic ability of pathogen reduced platelet, when compared to non-pathogen reduced platelets suspended in platelet additive solution.
What is the current status of trial NCT06535360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2020-09-01. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT06535360?
The interventions under investigation include: Platelet transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06535360?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.